Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 11/10/25 | Novo Nordisk (NVO) | coramitug for Transthyretin Amyloid Cardiomyopathy (ATTR-CM, Wild Type Or Hereditary) | Subscribers Only | Subscribers Only | Subscribers Only |
| 11/10/25 | Roche (RO) | RG7845 for Multiple Sclerosis (MS) | Subscribers Only | Subscribers Only | Subscribers Only |
| 11/10/25 | Roche (RO) | RG7845 for Multiple Sclerosis (MS) | Subscribers Only | Subscribers Only | Subscribers Only |
| 11/9/25 | Novo Nordisk (NVO) | Semaglutide (NASH) for Non-Alcoholic Steatohepatitis (NASH) | Subscribers Only | Subscribers Only | Subscribers Only |
| 11/8/25 | Amgen (AMGN) | Repatha for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 01/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
| 01/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |